Develops a platform for measuring proteins and protein variants in biological samples, and provides analysis services to academic institutions, research organizations, and biopharmaceutical companies.
10-K for FY2025, filed Feb 26, 2026The Nautilus VoyagerTM platform is designed to implement the Iterative Mapping method. The Nautilus Voyager platform integrates…View ↗
Building on the scientific and technical foundation established through our collaborations, we launched the Nautilus Iterative Mapping…View ↗
We intend to label and sell our products for research purposes only (“RUO”) and expect to sell them to academic institutions, life sciences…View ↗
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
Academic institutions, research organizations, and biopharmaceutical companies work with Nautilus through collaborations and the Early Access Program. Nautilus analyzes samples at its facility and delivers results through a cloud-based platform.
10-K for FY2025, filed Feb 26, 2026Collaborations and partnerships remain a foundational element of our go-to-market approach. We continue to work closely with select…View ↗
Building on the scientific and technical foundation established through our collaborations, we launched the Nautilus Iterative Mapping…View ↗
As we progress through the Early Access Program, we are preparing for broader commercial availability of the Nautilus Voyager platform and…View ↗
Services before platform sales
The earlier plan described an expanded early-access phase leading to a broad launch of instruments, reagents, and software sold directly. The latest report describes fee-for-service sample analysis at Nautilus before broader platform commercialization.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026We plan to initially target the life sciences proteomics research market and are currently entering the first phase of our product…View ↗
Competes with Thermo Fisher Scientific, Olink, Bruker, Agilent Technologies, Danaher, Becton, Dickinson, Quanterix, and Illumina
10-K for FY2025, filed Feb 26, 2026The life sciences market is highly competitive. There are other companies, both established and early-stage, that have indicated that they…View ↗
Loading...